The microbiome: a key piece in GLP-1 agonist treatments
Wegovy, Mounjaro, Saxenda, or Ozempic. Chances are you’ve heard of at least one of these medications. In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained enormous attention, particularly for their role in weight loss and weight management. And now, with the European Union’s recent approval of the first oral GLP-1 RA, their popularity is likely to grow even further.
Where have they come from?
GLP-1 Rs are not precisely a new development. They first appear more than 20 years ago. The first drug from this family, exenatide, was approved by FDA in 2005, as a blood glucose levels controller in adults with Type II diabetes. Since then, it has become the main treatment for this pathology, and its use was further amplified to other metabolic pathologies, including obesity.
Nowadays, several drugs from this class are available under different brand names. Most are administered by subcutaneous injection, either daily or weekly:
- Semaglutide
- Tirzepatide
- Liraglutide
- Dulaglutide
- Exenatide
Since these drugs act on processes associated with the digestive and endocrine systems, the gut microbiome may also play a role in their effects. Understanding this interaction is key to gaining a better understanding of individual responses to GLP-1 RAs and advancing towards more effective and personalized treatment strategies.
How do these drugs work?
GLP-1 RAs act by mimicking the effects of the GLP-1 hormone. This hormone plays a crucial role in glucose regulation, but its functions extend far beyond glycemic control. GLP-1 is involved in several processes affecting different organs and systems, including the pancreas, gastrointestinal tract, central nervous system, and immune system. Therefore, GLP-1 RA-based treatments have been associated with potential benefits beyond diabetes and obesity, including improvements in certain aspects of liver function, inflammation, and sleep apnea, as well as possible effects on bone and neurodegenerative disorders.
Among its main functions, GLP-1 stimulates insulin secretion in response to elevated blood glucose levels and reduces glucagon release, thereby helping to regulate blood glucose. Furthermore, it supports the survival of pancreatic β-cells. In the gastrointestinal tract, it slows intestinal motility, while in the central nervous system, it promotes satiety and reduces appetite.
GLP-1 is produced in response to the arrival of nutrients in the gut and is secreted by L cells, which are primarily located in the distal intestine. Short-chain fatty acids (SCFAs) play an important role in this process, particularly butyrate, which can stimulate the release of this hormone.
Although the mechanisms underlying appetite reduction are not yet fully understood, GLP-1 receptors are known to be present in various organs and regions of the central nervous system. Their activation may influence different pathways, connecting signals from the gut to brain regions such as the hypothalamus, which are involved in appetite regulation.
What role does the microbiome play?
Given the interaction between the gut microbiome and various metabolic processes, it is reasonable to suggest that it also plays a role in GLP-1 regulation. Gut microbial communities produce and transform a wide range of metabolites that can interact with this pathway, including short-chain fatty acids (SCFAs), bile acids, and lipopolysaccharides (LPS). Additionally, the microbiome may influence the degradation or bioavailability of this hormone. Several studies have also linked dysbiosis to a reduced response to GLP-1, as well as to obesity and impaired insulin function.
Multiple studies have reported associations between microbiome composition and activity, metabolism, and the response to GLP-1 RA treatments. These interactions may affect key metabolic processes, including glucose homeostasis, lipid metabolism, and appetite regulation. Furthermore, some evidence from animal models suggests that diabetes-associated cognitive decline may worsen following antibiotic treatment, highlighting a potential link between the microbiome, metabolism, and brain function.
Main hypotheses and current advances
Although the mechanisms underlying the interaction between GLP-1 RAs and the microbiome have not yet been fully characterized, several hypotheses are currently being investigated:
- GLP-1 RAs modulate the microbiome, and these changes contribute to weight loss.
- GLP-1 RAs induce metabolic changes through other pathways, which in turn modify the microbiome.
- The composition and activity of each individual’s microbiome may influence their response to treatment.
- Changes in appetite and eating habits associated with treatment may, in turn, alter the microbiome.
- GLP-1 RAs alter gut motility, leading to changes in the intestinal environment that may affect microbial communities.
When analyzing microbiome changes at the taxonomic level, it becomes more complex, as results may vary depending on the drug being studied, treatment duration, and the specific characteristics of the individuals involved. Some studies have reported an increase in potentially beneficial bacterial phyla, such as Bacteroidota, alongside a reduction in Firmicutes and Proteobacteria, which have been associated with obesity. However, other studies have described different microbial profiles, including a reduction in genera associated with obesity, such as Roseburia and Marvinbryantia.
These findings highlight the dynamic interaction between GLP-1 RA treatments and the microbiome, which may be influenced by the drug’s mechanism of action, treatment duration, changes in eating habits, and individual microbiome characteristics. These results underscore the potential of personalized therapies and raise the possibility that, for some patients with microbiome alterations, combining GLP-1 RAs with interventions aimed at modulating the microbiome could improve treatment response.
Challenges and future opportunities in nutrition
Despite the growing interest in the interaction between the microbiome and GLP-1 RAs, our understanding of this relationship remains limited. Most of the available evidence comes from studies involving patients with diabetes, so it remains unclear whether these findings can be replicated in other conditions. In the coming years, the combined use of different omics technologies and the integration of their data are expected to help us better understand the mechanisms linking the microbiome to treatment response.
Another common challenge in the available studies is the lack of detailed dietary information. Although diet is a key factor shaping microbiome composition and activity, as well as treatment response, its influence is not always adequately considered in study designs. Therefore, future studies should incorporate a more comprehensive assessment of dietary habits and investigate how interventions aimed at modulating the microbiome, such as prebiotics, postbiotics, and other strategies, may influence the response to GLP-1 RAs. This is particularly relevant for individuals who show a limited response to these treatments.
Understanding this interaction is important not only from a pharmacological perspective but also in the field of nutrition. GLP-1 RAs can significantly affect appetite and eating habits, potentially leading to changes in dietary intake. In this new scenario, food products may need to be adapted to meet the nutritional needs of people undergoing these treatments. This could involve prioritizing higher nutritional density, adequate protein and fiber content, and smaller portion sizes.
Therefore, understanding how these factors interact is becoming increasingly important. Integrating these can help us not only better understand treatment response but also develop more effective nutritional strategies tailored to each individual’s needs.
Bibliography
Gofron KK, Wasilewski A, Małgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025;17:1303. doi:10.3390/nu17081303.
Dinkov B, Pendicheva-Duhlenska D. The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review. Biomedicines. 2026;14:806. doi:10.3390/biomedicines14040806.
Johnson AJ, O’Sullivan EN, Valyasevi P, Metras B, Jang S, Shields-Cutler R, Hendel KR, Harindhanavudhi T, Teigen L. The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management. Can J Physiol Pharmacol. 2026;104:1-8. doi:10.1139/cjpp-2025-0219.
Kamath S, Chan NSL, Joyce P. GLP-1 agonists and the gut microbiome: A bidirectional relationship. Br J Clin Pharmacol. 2026;92(5):1309-1325. doi:10.1002/bcp.70487.